FT: Albanese’s Nov meeting with Xi comes as the two countries work to stabilise relations.

India's successful moon landing showcased some of what New Zealand can offer.

Plus: Spark, One and 2degrees update on their post-Gabrielle efforts to boost resilience.

'We’re thinking big and have immense confidence in our innovation from New Zealand.'

OPINION: I didn’t expect NZ to get back on track so quickly - and Luxon isn't even PM yet.

Will the rise of Ozempic keep eating into other companies' profits?

OPINION: Alcohol is a red herring when it comes to stopping sexual harassment at work.

FT: Climate change worries fuel breakthroughs in satellite tech that uses the sun's power.

Ambitious beverage startup faces criticism and regulatory turbulence.

Credit rating agency wary of National's plan for NZ's water infrastructure.

OPINION: I'm 53 and have been in a conservative fund for years. Should I make the switch?

"We don’t just move people around from project to project but let them put down roots."

OPINION: Labour has been comprehensively rejected by the electorate.

OPINION: Apec is important to NZ and there are many leaders Luxon will want to meet.

OPINON: Whether to float, fix and for how long is a common question for borrowers to ask.

Comments from the US Fed did little to alleviate fears.

Every price rise erodes NZ Inc's international competitiveness, say cargo owners.

Economist Gareth Kiernan says trends in current inflation are relatively good.

It sounds like sci-fi, but most of the tech is already here.

Since June 30, Fisher & Paykel Healthcare's stock has fallen by 14 per cent.